WallStreetZenWallStreetZen

NASDAQ: MNPR
Monopar Therapeutics Stock Ownership - Who owns Monopar Therapeutics?

Insider buying vs selling

Have Monopar Therapeutics insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Chandler RobinsonChief Executive Officer2024-01-012,327$0.34
$791.18Sell
Kim R. TsuchimotoChief Financial Officer2024-01-01505$0.34
$171.70Sell
Chandler RobinsonChief Executive Officer2023-12-318,469$0.34
$2.88kSell
Andrew CittadineChief Operating Officer2023-12-313,098$0.34
$1.05kSell
Kim R. TsuchimotoChief Financial Officer2023-12-314,073$0.34
$1.38kSell
Kim R. TsuchimotoChief Financial Officer2023-09-303,444$0.62
$2.14kSell
Andrew CittadineChief Operating Officer2023-09-302,624$0.62
$1.63kSell
Chandler RobinsonChief Executive Officer2023-09-307,172$0.62
$4.45kSell
Andrew CittadineChief Operating Officer2023-06-304,057$0.86
$3.47kSell
Chandler RobinsonChief Executive Officer2023-06-3010,269$0.86
$8.78kSell

1 of 2

MNPR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when MNPR insiders and whales buy or sell their stock.

MNPR Shareholders

What type of owners hold Monopar Therapeutics stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Arthur J. Klausner61.86%9,197,045$6.78MInsider
Michael J. 1. Brown32.32%4,805,470$3.54MInsider
Tactic Pharma LLC28.78%4,277,940$3.15MInsider
Chandler Robinson2.12%315,495$232.52kInsider
Andrew Paul Mazar1.27%188,792$139.14kInsider
Christopher M. Starr1.17%174,063$128.28kInsider
Andrew Cittadine0.35%51,770$38.15kInsider
Renaissance Technologies LLC0.32%48,086$35.44kInstitution
Vanguard Group Inc0.30%45,167$33.29kInstitution
Kim R. Tsuchimoto0.30%44,596$32.87kInsider

1 of 3

MNPR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
MNPR1.40%98.60%Net SellingNet Selling
BNOX0.07%0.00%
MTEM1.67%98.33%Net Buying
ELAB0.15%99.85%
EVAX1.18%0.00%

Monopar Therapeutics Stock Ownership FAQ

Who owns Monopar Therapeutics?

Monopar Therapeutics (NASDAQ: MNPR) is owned by 1.55% institutional shareholders, 109.32% Monopar Therapeutics insiders, and 0.00% retail investors. Arthur J. Klausner is the largest individual Monopar Therapeutics shareholder, owning 9.20M shares representing 52.69% of the company. Arthur J. Klausner's Monopar Therapeutics shares are currently valued at $6.26M.

If you're new to stock investing, here's how to buy Monopar Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.